JP2023540664A5 - - Google Patents

Info

Publication number
JP2023540664A5
JP2023540664A5 JP2022581404A JP2022581404A JP2023540664A5 JP 2023540664 A5 JP2023540664 A5 JP 2023540664A5 JP 2022581404 A JP2022581404 A JP 2022581404A JP 2022581404 A JP2022581404 A JP 2022581404A JP 2023540664 A5 JP2023540664 A5 JP 2023540664A5
Authority
JP
Japan
Prior art keywords
weight
composition
composition according
methyl
topical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022581404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540664A (ja
JP7813733B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/039646 external-priority patent/WO2022006129A1/en
Publication of JP2023540664A publication Critical patent/JP2023540664A/ja
Publication of JP2023540664A5 publication Critical patent/JP2023540664A5/ja
Application granted granted Critical
Publication of JP7813733B2 publication Critical patent/JP7813733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022581404A 2020-06-30 2021-06-29 Irak4阻害剤及びそれらの局所的使用方法 Active JP7813733B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063046531P 2020-06-30 2020-06-30
US63/046,531 2020-06-30
PCT/US2021/039646 WO2022006129A1 (en) 2020-06-30 2021-06-29 Irak4 inhibitors and topical uses thereof

Publications (3)

Publication Number Publication Date
JP2023540664A JP2023540664A (ja) 2023-09-26
JP2023540664A5 true JP2023540664A5 (cg-RX-API-DMAC7.html) 2024-06-26
JP7813733B2 JP7813733B2 (ja) 2026-02-13

Family

ID=79315566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022581404A Active JP7813733B2 (ja) 2020-06-30 2021-06-29 Irak4阻害剤及びそれらの局所的使用方法

Country Status (9)

Country Link
US (1) US20230390265A1 (cg-RX-API-DMAC7.html)
EP (1) EP4172163A4 (cg-RX-API-DMAC7.html)
JP (1) JP7813733B2 (cg-RX-API-DMAC7.html)
CN (1) CN116134038A (cg-RX-API-DMAC7.html)
AU (1) AU2021300110A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022027086A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186630A1 (cg-RX-API-DMAC7.html)
IL (1) IL298929A (cg-RX-API-DMAC7.html)
WO (1) WO2022006129A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3159624A1 (en) * 2019-11-05 2021-05-14 Dermira, Inc. Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101741294B1 (ko) * 2010-05-28 2017-05-29 히사미쓰 세이야꾸 가부시키가이샤 미소 돌기가 형성된 어레이를 갖는 디바이스
CA2929316C (en) * 2013-11-08 2021-12-28 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders
TW201825095A (zh) * 2016-11-28 2018-07-16 德商艾庫里斯抗感染治療有限公司 包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物
WO2018129364A1 (en) * 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
WO2019143971A2 (en) * 2018-01-18 2019-07-25 Sienna Biopharmaceuticals, Inc. Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure
KR20200138730A (ko) * 2018-03-29 2020-12-10 루모사 테라퓨틱스 캄파니 리미티드 가려움증 치료용 조성물 및 방법
US20210260055A1 (en) * 2018-06-21 2021-08-26 Dermavant Sciences GmbH Topical formulations of dgat1 inhibitors and their methods of use
US20200038392A1 (en) * 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
CA3159624A1 (en) * 2019-11-05 2021-05-14 Dermira, Inc. Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation

Similar Documents

Publication Publication Date Title
US10960006B2 (en) Topical formulations comprising tofacitinib
US7868044B2 (en) Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
JP2779303B2 (ja) 水系ゲルのレチノイド服用形態
US20100158993A1 (en) Topical Gel Compositions
RU2637408C2 (ru) Содержащие ретиноид композиции для местного применения типа эмульсии "масло в воде"
EP1858503B1 (en) Topical gels compositions
US8815953B2 (en) Formulations of vitamin K analogs for topical use
AU2016287636B2 (en) Diacerein or rhein topical formulations and uses thereof
EP2874619B1 (fr) Compositions pharmaceutiques topiques de type émulsion h/e contenant un rétinoïde
WO2022109626A1 (en) Gel, ointment, and foam formulations of tapinarof and methods of use
EP2854803B1 (fr) Compositions topiques sous forme de gel contenant un rétinoïde particulier solubilisé
WO2013036830A1 (en) Topical itraconazole formulations and uses thereof
EP2854801B1 (fr) Compositions topiques de type gel aqueux sous forme de suspension homogène d'un principe actif de la classe des rétinoïdes contenant au moins une silice hydrophobe
ZA200707357B (en) Detection of very virulent infectious bursal disease virus
CN101151028A (zh) 局部用凝胶组合物
JPWO2009041714A1 (ja) フリーラジカル性疾患用外用剤
WO2026067901A1 (zh) 一种局部药物组合物
EP4467159A1 (en) (4r)-3-(4-fluoro-2-hydroxyphenyl)-4-methyl-4,5-dihydro-1hpyrazole- 1-carboximidamide hydrochloride and dermal formulations thereof
US20180021290A1 (en) Diacerein or rhein topical formulations and uses thereof
HK1119058A (en) Topical gels compositions
JP2007502799A (ja) ラベンダスチンの医薬組成物